Abstract
Circulating microRNAs are novel and non-invasive tumor biomarkers for colorectal cancer (CRC) detection. In this study, we investigated miR-372 expression in serum and tissues in CRC and colorectal precancerous lesions (CPL) patients by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). Our data demonstrated that serum or tissue miR-372 levels were significantly up-regulated in patients with CRC or CPL, compared to healthy control (HC) subjects or normal tissues (P<0.05). High miR-372 expression in early colorectal cancer (ECRC) tissues were statistically significantly associated with tumor size (P<0.05), Tumor-Nodes-Metastasis (TNM) stage (P<0.05), and led to a worse overall survival (P=0.012). Postoperative serum miR-372 levels in ECRC patients significantly dropped, compared to the corresponding preoperative levels (P<0.05). The AUC of serum miR-372 expression for ECRC diagnosis was 0.854, which was significantly higher than that of combined tumor markers (CEA, CA19-9 and CA12-5) (0.613) (P<0.05). The sensitivity and specificity of serum miR-372 expression for ECRC diagnosis were 81.9 % and 73.3 %. All these findings provided an evidence that serum miR-372 could be a noninvasive biomarker for the early detection and prognosis of CRC.
Keywords: Colorectal cancer, diagnosis, miR-372, serum, prognosis.
Anti-Cancer Agents in Medicinal Chemistry
Title:Serum miR-372 is a Diagnostic and Prognostic Biomarker in Patients with Early Colorectal Cancer
Volume: 16 Issue: 4
Author(s): Jing Yu, Liyan Jin, Linhua Jiang, Ling Gao, Jin Zhou, You Hu, Wei Li, Qiaoming Zhi and Xinguo Zhu
Affiliation:
Keywords: Colorectal cancer, diagnosis, miR-372, serum, prognosis.
Abstract: Circulating microRNAs are novel and non-invasive tumor biomarkers for colorectal cancer (CRC) detection. In this study, we investigated miR-372 expression in serum and tissues in CRC and colorectal precancerous lesions (CPL) patients by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). Our data demonstrated that serum or tissue miR-372 levels were significantly up-regulated in patients with CRC or CPL, compared to healthy control (HC) subjects or normal tissues (P<0.05). High miR-372 expression in early colorectal cancer (ECRC) tissues were statistically significantly associated with tumor size (P<0.05), Tumor-Nodes-Metastasis (TNM) stage (P<0.05), and led to a worse overall survival (P=0.012). Postoperative serum miR-372 levels in ECRC patients significantly dropped, compared to the corresponding preoperative levels (P<0.05). The AUC of serum miR-372 expression for ECRC diagnosis was 0.854, which was significantly higher than that of combined tumor markers (CEA, CA19-9 and CA12-5) (0.613) (P<0.05). The sensitivity and specificity of serum miR-372 expression for ECRC diagnosis were 81.9 % and 73.3 %. All these findings provided an evidence that serum miR-372 could be a noninvasive biomarker for the early detection and prognosis of CRC.
Export Options
About this article
Cite this article as:
Yu Jing, Jin Liyan, Jiang Linhua, Gao Ling, Zhou Jin, Hu You, Li Wei, Zhi Qiaoming and Zhu Xinguo, Serum miR-372 is a Diagnostic and Prognostic Biomarker in Patients with Early Colorectal Cancer, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (4) . https://dx.doi.org/10.2174/1871520615666150716110406
DOI https://dx.doi.org/10.2174/1871520615666150716110406 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics Mitochondrial Toxicity in HAART: An Overview of In Vitro Evidence
Current Pharmaceutical Design Emerging Role of Terpenoids for the Treatment of Cancer: A Review
Mini-Reviews in Medicinal Chemistry Cytokines in Colitis-Associated Cancer: Potential Drug Targets?
Inflammation & Allergy - Drug Targets (Discontinued) VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Efficacy of Therapy with c-Met/HGF Inhibitors in Solid Tumors: A Systematic Review Based on 24 Clinical Trials
Clinical Cancer Drugs Pivotal Role of the Interaction Between Herbal Medicines and Gut Microbiota on Disease Treatment
Current Drug Targets 2-Nucleobase-substituted 4,6-Diaminotriazine Analogs: Synthesis and Anti-cancer Activity in 5-Fluorouracil-sensitive and Resistant Colorectal Cancer Cells
Current Medicinal Chemistry Hypoxia Affects Mitochondrial Stress and Facilitates Tumor Metastasis of Colorectal Cancer Through Slug SUMOylation
Current Molecular Medicine Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Scalarane Sesterterpenoids
Current Bioactive Compounds Supramolecular Chiro-Biomedical Assays and Enantioselective HPLC Analyses for Evaluation of Profens as Non-Steroidal Anti-Inflammatory Drugs, Potential Anticancer Agents and Common Xenobiotics
Current Drug Discovery Technologies Physiology of Folic Acid in Health and Disease
Current Drug Metabolism Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence
Current Pharmaceutical Design Recent Patents on Biomedical Devices and Nanomaterials for Hyperthermal Therapy of Cancer
Recent Patents on Nanomedicine Novel Patented Src Kinase Inhibitor
Current Medicinal Chemistry A3 Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Editorial (Hot Topic: Computer-Aided Drug Design, Synthesis and Evaluation of New Anti-Cancer Drugs)
Current Topics in Medicinal Chemistry Cardiovascular Adverse Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Combined Cancer Therapy with Non-Conventional Drugs: All Roads Lead to AMPK
Mini-Reviews in Medicinal Chemistry